关键词: font-size:medium, ">维得利珠单抗；炎症性肠病；有效性；安全性；经济性；快速卫生技术评估

Abstract: Objective：To evaluate the efficacy， safety and economy of vedolizumab (VDZ) in the treatment of inflammatory bowel disease (IBD)，and provide evidence-based medical evidence for clinical drug decision. Methods： PubMed， the Cochrane Library， Embase， CNKI， Wanfang databases and Health Technology Assessment (HTA) websites were systematically searched. According to the inclusion and exclusion criteria，the researchers screened the literature， extracted data， and conducted quality evaluation and qualitative synthesis of the literature. Results： A total of 31 articles were included， including 2 HTA reports， 17 systematic reviews/meta-analyses， and 12 economic studies. In terms of effectiveness， VDZ effectively improved the clinical response rate， clinical remission rate， steroid-free remission rate， and mucosal healing rate in IBD patients. In terms of safety， the incidence of general adverse events， serious adverse events， discontinuation due to adverse events， serious infection， and infusion reactions of VDZ was comparable to placebo， and superior to other IBD biologics. The incidence of adverse reactions of vedolizumab was low and mild to moderate， among which the incidence of rhinitis and pharynx was higher. In terms of economy， based on the Chinese healthcare system， VDZ was more economical than traditional drugs for Crohn′s disease patients who have never received anti-TNF-α therapy or failed anti-TNF-α therapy. VDZ was more economical than infliximab for patients with moderate-to-severe active ulcerative colitis who have not previously received anti-TNF-α therapy. Conclusion： VDZ is safe， effective and economical in the treatment of IBD.

Key words: font-size:medium, ">Vedolizumab； Inflammatory bowel disease； Effectiveness； Security； Economy； Rapid health technology assessment